BioCentury
ARTICLE | Clinical News

VEGF165 gene medicine: Phase II

November 15, 1999 8:00 AM UTC

An interim analysis of 27 patients showed an increase in the number of blood vessels in patients receiving VEGF via intravascular administration of VLTS's plasmid or an adenoviral vector, whereas no increase was seen for placebo. VLTS said that its plasmid was as effective as adenoviral delivery of the gene. No adverse events were seen with VLTS's plasmid. ...